Latest News & Features
Careers
The exodus of patent trial litigators was ‘an easy choice’ due to their new employer’s ‘scale, vision and entrepreneurial culture’. 18 September 2025
Europe
A UPC Court of Appeal decision establishes a new benchmark for what constitutes imminent infringement in pharmaceutical patent litigation, particularly regarding generics’ pre-launch preparations, writes Mike Gruber of Carpmaels & Ransford. 18 September 2025
Europe
From trademark decisions to judicial writing, the IP community is embracing AI but questions loom about quality, precedents, and jurisdictional limits. Muireann Bolger reports from Marques’ annual meeting. 18 September 2025
Americas
A notable Ninth Circuit ruling raises questions about disclosure that trade secrets plaintiffs will want to consider—particularly with regards to timing, says Carolyn Hoecker Luedtke of Munger, Tolles & Olson. 17 September 2025
Asia
From drug discovery to post-market surveillance, AI is rewriting the rules in pharma—and the patent system is struggling to keep up. At AIPPI’s World Congress 2025, Marisa Woutersen hears experts debate AI disclosure, inventive step, and inventorship. 16 September 2025
Asia
How can companies stay ahead in trade secret protection, from adapting to new legislation and emerging case law to managing cross-border risks? Marisa Woutersen reports from the AIPPI World Congress 2025. 15 September 2025
Americas
After four years as associate general counsel at a pharmaceutical company, the partner returns to private practice with experience across patents, trademarks, copyright and trade secret litigation. 12 September 2025
Americas
Deal resolves just one case in Regeneron’s roll-call of actions against competitors looking to launch versions of a $6bn-a-year blockbuster eye-disease treatment. 11 September 2025
Careers
The firm’s medtech practice will be led by a partner with experience in digital health, medical devices, and emerging technologies, with particular expertise in advising startups. 10 September 2025
Americas
Federal oversight, funding cuts, and patent uncertainties are forcing universities, startups, and pharma companies to reassess partnership models, finds Marisa Woutersen. 9 September 2025